<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673920</url>
  </required_header>
  <id_info>
    <org_study_id>ACT4394g</org_study_id>
    <secondary_id>WA20496</secondary_id>
    <nct_id>NCT00673920</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy</brief_title>
  <acronym>FEATURE</acronym>
  <official_title>A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of ocrelizumab, compared to placebo, in&#xD;
      patients with active rheumatoid arthritis who have an inadequate response to methotrexate&#xD;
      therapy. Patients will be randomized 2:2:1 to receive 1) infusions of ocrelizumab 200mg iv on&#xD;
      Days 1 and 15, 2) infusions of ocrelizumab 400mg iv on Day 1 and placebo iv on Day 15, or 3)&#xD;
      infusions of placebo iv on Days 1 and 15. At the end of the placebo-controlled treatment&#xD;
      period at 24 weeks, patients in groups 1 and 3 will be re-randomized to receive either a&#xD;
      single infusion of 400mg iv ocrelizumab or 2 infusions of 200mg iv ocrelizumab, and group 2&#xD;
      will receive a second single infusion of 400mg iv ocrelizumab. All patients will receive a&#xD;
      stable dose of concomitant methotrexate (7.5-25mg/week) throughout the study. The anticipated&#xD;
      time on study treatment is 1-2 years. Target number of patients to be enrolled in this trial&#xD;
      is 300.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on analysis of results and consideration of available treatments, the overall benefit to&#xD;
    risk profile of ocrelizumab was not favorable in RA.&#xD;
  </why_stopped>
  <start_date type="Actual">April 24, 2008</start_date>
  <completion_date type="Actual">October 26, 2009</completion_date>
  <primary_completion_date type="Actual">October 26, 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology (ACR) 20 Response</measure>
    <time_frame>Week 24</time_frame>
    <description>ACR20 response: greater than or equal to (≥) 20% improvement in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) Physician's global assessment of disease activity, 2) participant assessment of disease activity, 3) Patient Assessment of Pain (visual analog scale [VAS]), 4) participant assessment of functional disability via a Health Assessment Questionnaire (HAQ), and 5) erythrocyte sedimentation rate (ESR) at each visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Remission (DAS28 &lt; 2.6)</measure>
    <time_frame>Week 24</time_frame>
    <description>The DAS28 was derived from assessments of erythrocyte sedimentation rate (ESR) measured in millimeters per hour (mm/h), tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), and Patient's Global Assessment of disease activity according to 100--millimeter (mm) Visual Analog Scale (VAS). DAS28 score was calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity. The change from Week 24 to Week 40 was averaged among all participants, where negative changes indicated an improvement in disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28 From Baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>The DAS28 was derived from assessments of erythrocyte sedimentation rate (ESR) measured in millimeters per hour (mm/h), tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), and Patient's Global Assessment of disease activity according to 100--millimeter (mm) Visual Analog Scale (VAS). DAS28 score was calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity. The change from Week 24 to Week 40 was averaged among all participants, where negative changes indicated an improvement in disease activity. The change is the difference in adjusted mean change from baseline in DAS28 between ocrelizumab 400 x 1 and ocrelizumab 200 x 2 with placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European League Against Rheumatism (EULAR) Response Rates (Categorical DAS Responders)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR50 Response</measure>
    <time_frame>Week 24</time_frame>
    <description>The ACR50 response at any time was defined as &gt;/=50% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 50% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR70 Response</measure>
    <time_frame>Week 24</time_frame>
    <description>The ACR70 response at any time was defined as &gt;/=70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Individual Parameters of the ACR Core Set</measure>
    <time_frame>Week 24</time_frame>
    <description>Change in the scores of the following parameters of ACR core set relative to respective baseline scores was measured: SJC (28 and 66 joints) and TJC (28 and 66 joints), patient's global assessment and physician's global assessment based on disease activity (both are expressed by VAS [0 = no disease activity to 100 = maximum disease activity]), HAQ (based on HAQ disability index [HAQDI]) which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst), pain assessment using a VAS ranging from score 0 (no pain) to 100 (unbearable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Individual Parameters of the ACR Core Set: C-Reactive Protein (CRP) Concentration</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Individual Parameters of the ACR Core Set: Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Reduction of Greater Than or Equal to 0.25 Units in the HAQ-DI Score</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 Subscale and Summary Scores From Baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>Improved, change &gt; 5.42; Unchanged, -5.42 &lt;= Change &lt;= 5.42; Worsened, change &lt; -5.42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FACIT-F Fatigue Assessment From Baseline</measure>
    <time_frame>Baseline, Weeks 4, 12, and 24</time_frame>
    <description>The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR20 Response</measure>
    <time_frame>Week 48</time_frame>
    <description>ACR20 response: greater than or equal to (≥) 20% improvement in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) Physician's global assessment of disease activity, 2) participant assessment of disease activity, 3) Patient Assessment of Pain (visual analog scale [VAS]), 4) participant assessment of functional disability via a Health Assessment Questionnaire (HAQ), and 5) erythrocyte sedimentation rate (ESR) at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR50 Response</measure>
    <time_frame>Week 48</time_frame>
    <description>The ACR50 response at any time was defined as &gt;/=50% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 50% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving an ACR70 Response</measure>
    <time_frame>Week 48</time_frame>
    <description>The ACR70 response at any time was defined as &gt;/=70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28 Remission (DAS28 &lt; 2.6)</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Serum Concentration of Ocrelizumab Following First Infusion</measure>
    <time_frame>Week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Csecond: Maximum Observed Serum Concentration of Ocrelizumab Following Second Infusion</measure>
    <time_frame>Day 15 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">314</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocrelizumab 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocrelizumab 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocrelizumab 200mg/ Ocrelizumab 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocrelizumab 200mg/ Ocrelizumab 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocrelizumab 400mg/ Ocrelizumab 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/ Ocrelizumab 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/ Ocrelizumab 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Oral or parenteral repeating dose</description>
    <arm_group_label>Ocrelizumab 200mg</arm_group_label>
    <arm_group_label>Ocrelizumab 200mg/ Ocrelizumab 200mg</arm_group_label>
    <arm_group_label>Ocrelizumab 200mg/ Ocrelizumab 400mg</arm_group_label>
    <arm_group_label>Ocrelizumab 400mg</arm_group_label>
    <arm_group_label>Ocrelizumab 400mg/ Ocrelizumab 400mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo/ Ocrelizumab 200mg</arm_group_label>
    <arm_group_label>Placebo/ Ocrelizumab 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocrelizumab</intervention_name>
    <description>Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).&#xD;
Ocrelizumab was administered in combination with Methotrexate.</description>
    <arm_group_label>Ocrelizumab 200mg</arm_group_label>
    <arm_group_label>Ocrelizumab 200mg/ Ocrelizumab 200mg</arm_group_label>
    <arm_group_label>Ocrelizumab 200mg/ Ocrelizumab 400mg</arm_group_label>
    <arm_group_label>Ocrelizumab 400mg</arm_group_label>
    <arm_group_label>Ocrelizumab 400mg/ Ocrelizumab 400mg</arm_group_label>
    <arm_group_label>Placebo/ Ocrelizumab 200mg</arm_group_label>
    <arm_group_label>Placebo/ Ocrelizumab 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous repeating dose</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo/ Ocrelizumab 200mg</arm_group_label>
    <arm_group_label>Placebo/ Ocrelizumab 400mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adult patients, ≥ 18 years of age&#xD;
&#xD;
          -  Active rheumatoid arthritis&#xD;
&#xD;
          -  Inadequate treatment with any DMARD other than methotrexate&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid&#xD;
             arthritis&#xD;
&#xD;
          -  Concurrent treatment with any DMARD other than methotrexate&#xD;
&#xD;
          -  Previous treatment with any cell-depleting therapies&#xD;
&#xD;
          -  Any surgical procedure in past 12 weeks, or planned within 48 weeks after baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Dummer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>November 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2020</results_first_posted>
  <disposition_first_submitted>June 28, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>June 28, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 4, 2013</disposition_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ocrelizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Screening was completed within 28 days prior to randomization. This may have been extended by an additional 56 days, up to a maximum of 84 days, if washout from the respective disease modifying anti-rheumatic drugs (DMARDs) or if immunization was required.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
        </group>
        <group group_id="P2">
          <title>Ocrelizumab 400mg</title>
          <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
        </group>
        <group group_id="P3">
          <title>Ocrelizumab 200mg</title>
          <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
        </group>
        <group group_id="P4">
          <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
          <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="P5">
          <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
          <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="P6">
          <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
          <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="P7">
          <title>Placebo/ Ocrelizumab 200mg</title>
          <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="P8">
          <title>Placebo/ Ocrelizumab 400mg</title>
          <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline up to Week 48</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="133"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="126"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient therapeutic response</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of selection criteria at entry</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative/Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event/intercurrent illness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 24 to Week 48</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="61"/>
                <participants group_id="P6" count="109"/>
                <participants group_id="P7" count="29"/>
                <participants group_id="P8" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="60"/>
                <participants group_id="P5" count="61"/>
                <participants group_id="P6" count="106"/>
                <participants group_id="P7" count="28"/>
                <participants group_id="P8" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse event/intercurrent illness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient therapeutic response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adminstrative/Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics not provided for Participants who were re-randomized at Week 24 (Cycle 2)</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
        </group>
        <group group_id="B2">
          <title>Ocrelizumab 400mg</title>
          <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
        </group>
        <group group_id="B3">
          <title>Ocrelizumab 200mg</title>
          <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
        </group>
        <group group_id="B4">
          <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
          <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="B5">
          <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
          <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="B6">
          <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
          <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="B7">
          <title>Placebo/ Ocrelizumab 200mg</title>
          <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="B8">
          <title>Placebo/ Ocrelizumab 400mg</title>
          <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="131"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="0"/>
            <count group_id="B8" value="0"/>
            <count group_id="B9" value="312"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" spread="11.45"/>
                    <measurement group_id="B2" value="52.3" spread="11.14"/>
                    <measurement group_id="B3" value="53.0" spread="11.15"/>
                    <measurement group_id="B9" value="52.8" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B9" value="254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B9" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B9" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B9" value="256"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B9" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B9" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B9" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B9" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B9" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With American College of Rheumatology (ACR) 20 Response</title>
        <description>ACR20 response: greater than or equal to (≥) 20% improvement in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) Physician's global assessment of disease activity, 2) participant assessment of disease activity, 3) Patient Assessment of Pain (visual analog scale [VAS]), 4) participant assessment of functional disability via a Health Assessment Questionnaire (HAQ), and 5) erythrocyte sedimentation rate (ESR) at each visit.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology (ACR) 20 Response</title>
          <description>ACR20 response: greater than or equal to (≥) 20% improvement in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) Physician's global assessment of disease activity, 2) participant assessment of disease activity, 3) Patient Assessment of Pain (visual analog scale [VAS]), 4) participant assessment of functional disability via a Health Assessment Questionnaire (HAQ), and 5) erythrocyte sedimentation rate (ESR) at each visit.</description>
          <population>ITT Population (original randomization)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" lower_limit="17.1" upper_limit="39.1"/>
                    <measurement group_id="O2" value="37.6" lower_limit="28.8" upper_limit="46.4"/>
                    <measurement group_id="O3" value="52.7" lower_limit="44.1" upper_limit="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Remission (DAS28 &lt; 2.6)</title>
        <description>The DAS28 was derived from assessments of erythrocyte sedimentation rate (ESR) measured in millimeters per hour (mm/h), tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), and Patient's Global Assessment of disease activity according to 100--millimeter (mm) Visual Analog Scale (VAS). DAS28 score was calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity. The change from Week 24 to Week 40 was averaged among all participants, where negative changes indicated an improvement in disease activity.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Disease Activity Score 28 (DAS28) Remission (DAS28 &lt; 2.6)</title>
          <description>The DAS28 was derived from assessments of erythrocyte sedimentation rate (ESR) measured in millimeters per hour (mm/h), tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), and Patient's Global Assessment of disease activity according to 100--millimeter (mm) Visual Analog Scale (VAS). DAS28 score was calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity. The change from Week 24 to Week 40 was averaged among all participants, where negative changes indicated an improvement in disease activity.</description>
          <population>ITT Population (original randomization)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in DAS28 From Baseline</title>
        <description>The DAS28 was derived from assessments of erythrocyte sedimentation rate (ESR) measured in millimeters per hour (mm/h), tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), and Patient's Global Assessment of disease activity according to 100--millimeter (mm) Visual Analog Scale (VAS). DAS28 score was calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity. The change from Week 24 to Week 40 was averaged among all participants, where negative changes indicated an improvement in disease activity. The change is the difference in adjusted mean change from baseline in DAS28 between ocrelizumab 400 x 1 and ocrelizumab 200 x 2 with placebo.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in DAS28 From Baseline</title>
          <description>The DAS28 was derived from assessments of erythrocyte sedimentation rate (ESR) measured in millimeters per hour (mm/h), tender joint count on 28 joints (TJC28), swollen joint count on 28 joints (SJC28), and Patient's Global Assessment of disease activity according to 100--millimeter (mm) Visual Analog Scale (VAS). DAS28 score was calculated as [0.56 × square root of TJC] + [0.28 × square root of SJC] + [0.70 × natural log (ESR)] + [0.014 × VAS]. DAS28 score could range from 0 to 10, where higher score represented higher disease activity. The change from Week 24 to Week 40 was averaged among all participants, where negative changes indicated an improvement in disease activity. The change is the difference in adjusted mean change from baseline in DAS28 between ocrelizumab 400 x 1 and ocrelizumab 200 x 2 with placebo.</description>
          <population>ITT Population (original randomization)</population>
          <units>Units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="1.293"/>
                    <measurement group_id="O2" value="-1.60" spread="1.374"/>
                    <measurement group_id="O3" value="-1.67" spread="1.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European League Against Rheumatism (EULAR) Response Rates (Categorical DAS Responders)</title>
        <time_frame>Week 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>European League Against Rheumatism (EULAR) Response Rates (Categorical DAS Responders)</title>
          <population>ITT Population (original randomization)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="62.4"/>
                    <measurement group_id="O3" value="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Moderate Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Good Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3"/>
                    <measurement group_id="O2" value="52.1"/>
                    <measurement group_id="O3" value="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Moderate Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1"/>
                    <measurement group_id="O2" value="39.3"/>
                    <measurement group_id="O3" value="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 Good Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="8.5"/>
                    <measurement group_id="O3" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="41.9"/>
                    <measurement group_id="O3" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Moderate Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="49.6"/>
                    <measurement group_id="O3" value="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Good Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="39.3"/>
                    <measurement group_id="O3" value="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Moderate Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                    <measurement group_id="O2" value="49.6"/>
                    <measurement group_id="O3" value="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Good Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="41.0"/>
                    <measurement group_id="O3" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 Moderate Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="48.7"/>
                    <measurement group_id="O3" value="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 Good Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="10.3"/>
                    <measurement group_id="O3" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 No Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4"/>
                    <measurement group_id="O2" value="44.4"/>
                    <measurement group_id="O3" value="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Moderate Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9"/>
                    <measurement group_id="O2" value="41.0"/>
                    <measurement group_id="O3" value="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Good Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="14.5"/>
                    <measurement group_id="O3" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR50 Response</title>
        <description>The ACR50 response at any time was defined as &gt;/=50% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 50% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
        <time_frame>Week 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR50 Response</title>
          <description>The ACR50 response at any time was defined as &gt;/=50% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 50% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
          <population>ITT Population (original randomization)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR70 Response</title>
        <description>The ACR70 response at any time was defined as &gt;/=70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
        <time_frame>Week 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR70 Response</title>
          <description>The ACR70 response at any time was defined as &gt;/=70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
          <population>ITT Population (original randomization)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Individual Parameters of the ACR Core Set</title>
        <description>Change in the scores of the following parameters of ACR core set relative to respective baseline scores was measured: SJC (28 and 66 joints) and TJC (28 and 66 joints), patient's global assessment and physician's global assessment based on disease activity (both are expressed by VAS [0 = no disease activity to 100 = maximum disease activity]), HAQ (based on HAQ disability index [HAQDI]) which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst), pain assessment using a VAS ranging from score 0 (no pain) to 100 (unbearable pain).</description>
        <time_frame>Week 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Individual Parameters of the ACR Core Set</title>
          <description>Change in the scores of the following parameters of ACR core set relative to respective baseline scores was measured: SJC (28 and 66 joints) and TJC (28 and 66 joints), patient's global assessment and physician's global assessment based on disease activity (both are expressed by VAS [0 = no disease activity to 100 = maximum disease activity]), HAQ (based on HAQ disability index [HAQDI]) which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst), pain assessment using a VAS ranging from score 0 (no pain) to 100 (unbearable pain).</description>
          <population>ITT Population (original randomization)</population>
          <units>Units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SJC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6"/>
                    <measurement group_id="O2" value="-7.5"/>
                    <measurement group_id="O3" value="-8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TJC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2"/>
                    <measurement group_id="O2" value="-10.2"/>
                    <measurement group_id="O3" value="-12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's global assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6"/>
                    <measurement group_id="O2" value="-21.2"/>
                    <measurement group_id="O3" value="-24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physician's global assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.0"/>
                    <measurement group_id="O2" value="-24.3"/>
                    <measurement group_id="O3" value="-26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient's pain assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0"/>
                    <measurement group_id="O2" value="-17.2"/>
                    <measurement group_id="O3" value="-21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2"/>
                    <measurement group_id="O2" value="-0.4"/>
                    <measurement group_id="O3" value="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Individual Parameters of the ACR Core Set: C-Reactive Protein (CRP) Concentration</title>
        <time_frame>Week 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Individual Parameters of the ACR Core Set: C-Reactive Protein (CRP) Concentration</title>
          <population>ITT Population (original randomization)</population>
          <units>mg/dL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2"/>
                    <measurement group_id="O2" value="-1.0"/>
                    <measurement group_id="O3" value="-0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Individual Parameters of the ACR Core Set: Erythrocyte Sedimentation Rate (ESR)</title>
        <time_frame>Week 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Individual Parameters of the ACR Core Set: Erythrocyte Sedimentation Rate (ESR)</title>
          <population>ITT Population (original randomization)</population>
          <units>mm/hr</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0"/>
                    <measurement group_id="O2" value="-14.2"/>
                    <measurement group_id="O3" value="-11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Reduction of Greater Than or Equal to 0.25 Units in the HAQ-DI Score</title>
        <time_frame>Week 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Reduction of Greater Than or Equal to 0.25 Units in the HAQ-DI Score</title>
          <population>ITT Population (original randomization)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="25.6" upper_limit="49.4"/>
                    <measurement group_id="O2" value="55.6" lower_limit="46.6" upper_limit="64.6"/>
                    <measurement group_id="O3" value="58.8" lower_limit="50.3" upper_limit="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SF-36 Subscale and Summary Scores From Baseline</title>
        <description>Improved, change &gt; 5.42; Unchanged, -5.42 &lt;= Change &lt;= 5.42; Worsened, change &lt; -5.42</description>
        <time_frame>Week 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SF-36 Subscale and Summary Scores From Baseline</title>
          <description>Improved, change &gt; 5.42; Unchanged, -5.42 &lt;= Change &lt;= 5.42; Worsened, change &lt; -5.42</description>
          <population>ITT Population (original randomization)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mental Component Summary Category Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0"/>
                    <measurement group_id="O2" value="34.9"/>
                    <measurement group_id="O3" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary Category Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Summary Category Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="15.1"/>
                    <measurement group_id="O3" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0"/>
                    <measurement group_id="O2" value="45.3"/>
                    <measurement group_id="O3" value="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0"/>
                    <measurement group_id="O2" value="51.9"/>
                    <measurement group_id="O3" value="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FACIT-F Fatigue Assessment From Baseline</title>
        <description>The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.</description>
        <time_frame>Baseline, Weeks 4, 12, and 24</time_frame>
        <population>ITT Population (original randomization)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FACIT-F Fatigue Assessment From Baseline</title>
          <description>The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.</description>
          <population>ITT Population (original randomization)</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="131"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.13" spread="10.616"/>
                    <measurement group_id="O2" value="25.33" spread="11.313"/>
                    <measurement group_id="O3" value="24.74" spread="11.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="117"/>
                    <count group_id="O3" value="131"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.94" spread="11.371"/>
                    <measurement group_id="O2" value="28.60" spread="11.231"/>
                    <measurement group_id="O3" value="30.71" spread="11.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="114"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.42" spread="12.015"/>
                    <measurement group_id="O2" value="32.09" spread="12.368"/>
                    <measurement group_id="O3" value="33.09" spread="10.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="127"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.47" spread="12.406"/>
                    <measurement group_id="O2" value="31.38" spread="11.346"/>
                    <measurement group_id="O3" value="33.18" spread="11.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR20 Response</title>
        <description>ACR20 response: greater than or equal to (≥) 20% improvement in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) Physician's global assessment of disease activity, 2) participant assessment of disease activity, 3) Patient Assessment of Pain (visual analog scale [VAS]), 4) participant assessment of functional disability via a Health Assessment Questionnaire (HAQ), and 5) erythrocyte sedimentation rate (ESR) at each visit.</description>
        <time_frame>Week 48</time_frame>
        <population>Study extension period included all participants who were re-randomized at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR20 Response</title>
          <description>ACR20 response: greater than or equal to (≥) 20% improvement in tender or swollen joint counts and 20% improvement in 3 of the following 5 criteria: 1) Physician's global assessment of disease activity, 2) participant assessment of disease activity, 3) Patient Assessment of Pain (visual analog scale [VAS]), 4) participant assessment of functional disability via a Health Assessment Questionnaire (HAQ), and 5) erythrocyte sedimentation rate (ESR) at each visit.</description>
          <population>Study extension period included all participants who were re-randomized at Week 24.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="109"/>
                <count group_id="O7" value="29"/>
                <count group_id="O8" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="59.0"/>
                    <measurement group_id="O5" value="54.1"/>
                    <measurement group_id="O6" value="56.9"/>
                    <measurement group_id="O7" value="44.8"/>
                    <measurement group_id="O8" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR50 Response</title>
        <description>The ACR50 response at any time was defined as &gt;/=50% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 50% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
        <time_frame>Week 48</time_frame>
        <population>Study extension period included all participants who were re-randomized at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR50 Response</title>
          <description>The ACR50 response at any time was defined as &gt;/=50% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 50% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
          <population>Study extension period included all participants who were re-randomized at Week 24.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="109"/>
                <count group_id="O7" value="29"/>
                <count group_id="O8" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="36.1"/>
                    <measurement group_id="O5" value="27.9"/>
                    <measurement group_id="O6" value="34.9"/>
                    <measurement group_id="O7" value="20.7"/>
                    <measurement group_id="O8" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving an ACR70 Response</title>
        <description>The ACR70 response at any time was defined as &gt;/=70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
        <time_frame>Week 48</time_frame>
        <population>Study extension period included all participants who were re-randomized at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an ACR70 Response</title>
          <description>The ACR70 response at any time was defined as &gt;/=70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) Patient's global assessment of disease activity according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/dL).</description>
          <population>Study extension period included all participants who were re-randomized at Week 24.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="109"/>
                <count group_id="O7" value="29"/>
                <count group_id="O8" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="19.7"/>
                    <measurement group_id="O5" value="16.4"/>
                    <measurement group_id="O6" value="19.3"/>
                    <measurement group_id="O7" value="6.9"/>
                    <measurement group_id="O8" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28 Remission (DAS28 &lt; 2.6)</title>
        <time_frame>Week 48</time_frame>
        <population>Study extension period included all participants who were re-randomized at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 400mg</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O5">
            <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O6">
            <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
            <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O7">
            <title>Placebo/ Ocrelizumab 200mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
          <group group_id="O8">
            <title>Placebo/ Ocrelizumab 400mg</title>
            <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28 Remission (DAS28 &lt; 2.6)</title>
          <population>Study extension period included all participants who were re-randomized at Week 24.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="109"/>
                <count group_id="O7" value="29"/>
                <count group_id="O8" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="13.1"/>
                    <measurement group_id="O5" value="3.3"/>
                    <measurement group_id="O6" value="11.0"/>
                    <measurement group_id="O7" value="6.9"/>
                    <measurement group_id="O8" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Serum Concentration of Ocrelizumab Following First Infusion</title>
        <time_frame>Week 24, 48</time_frame>
        <population>Placebo population was excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200mg - Cycle 2</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate in Cycle 2</description>
          </group>
          <group group_id="O3">
            <title>Ocrelizumab 400mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
          </group>
          <group group_id="O4">
            <title>Ocrelizumab 400mg - Cycle 2</title>
            <description>Participants who received a single infusion of 400 mg Ocrelizumab + Methotraxate in Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Serum Concentration of Ocrelizumab Following First Infusion</title>
          <population>Placebo population was excluded from the analysis.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" spread="63.8"/>
                    <measurement group_id="O2" value="67.7" spread="27.0"/>
                    <measurement group_id="O3" value="133" spread="38.5"/>
                    <measurement group_id="O4" value="137" spread="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Csecond: Maximum Observed Serum Concentration of Ocrelizumab Following Second Infusion</title>
        <time_frame>Day 15 of Cycles 1 and 2</time_frame>
        <population>Population included all participants who received second Ocrelizumab infusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Ocrelizumab 200mg - Cycle 1</title>
            <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
          </group>
          <group group_id="O2">
            <title>Ocrelizumab 200mg - Cycle 2</title>
            <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate in Cycle 2</description>
          </group>
        </group_list>
        <measure>
          <title>Csecond: Maximum Observed Serum Concentration of Ocrelizumab Following Second Infusion</title>
          <population>Population included all participants who received second Ocrelizumab infusion.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" spread="18.0"/>
                    <measurement group_id="O2" value="77.6" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline up to 17 months</time_frame>
      <desc>Re-randomized Safety Population: All patients (including those not re-randomized at Week 24) who received any part of the second course and provided at least one assessment of safety prior to Week 48 were included in the Re-randomized Safety Population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received matching placebo:&#xD;
on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)&#xD;
on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)</description>
        </group>
        <group group_id="E2">
          <title>Ocrelizumab 400mg</title>
          <description>Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.</description>
        </group>
        <group group_id="E3">
          <title>Ocrelizumab 200mg</title>
          <description>Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.</description>
        </group>
        <group group_id="E4">
          <title>Ocrelizumab 200mg/ Ocrelizumab 200mg</title>
          <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="E5">
          <title>Ocrelizumab 200mg/ Ocrelizumab 400mg</title>
          <description>Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="E6">
          <title>Ocrelizumab 400mg/ Ocrelizumab 400mg</title>
          <description>Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="E7">
          <title>Placebo/ Ocrelizumab 200mg</title>
          <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
        <group group_id="E8">
          <title>Placebo/ Ocrelizumab 400mg</title>
          <description>Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHIECTASIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>MYCOBACTERIUM ABSCESSUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>PROSTATE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.05</frequency_threshold>
        <default_vocab>MedRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="117"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="131"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="86" subjects_at_risk="109"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="29"/>
                <counts group_id="E8" subjects_affected="22" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INFUSION RELATED REACTION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="117"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="131"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="61"/>
                <counts group_id="E5" events="17" subjects_affected="17" subjects_at_risk="61"/>
                <counts group_id="E6" events="28" subjects_affected="28" subjects_at_risk="109"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="117"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="131"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="61"/>
                <counts group_id="E6" events="14" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="117"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

